Expanding the therapeutic landscape: ezetimibe as non-statin therapy for dyslipidemia
Jeongmin Lee, Seung-Hwan Lee
Korean J Intern Med. 2023;38(6):797-809. Published online 2023 Oct 20 DOI: https://doi.org/10.3904/kjim.2023.243
Citations to this article as recorded by 
Impact of early initiation of ezetimibe in patients with acute coronary syndrome: A systematic review and meta-analysis
Kunal Mahajan, Lakshmi Nagendra, Anil Dhall, Deep Dutta
European Journal of Internal Medicine.2024; 124: 99. CrossRef
The Pleiotropic Effects of Lipid-Modifying Interventions: Exploring Traditional and Emerging Hypolipidemic Therapies
Dimitris Kounatidis, Nikolaos Tentolouris, Natalia G. Vallianou, Iordanis Mourouzis, Irene Karampela, Theodora Stratigou, Eleni Rebelos, Marina Kouveletsou, Vasileios Stamatopoulos, Eleni Tsaroucha, Maria Dalamaga
Metabolites.2024; 14(7): 388. CrossRef
The functions of apolipoproteins and lipoproteins in health and disease
Zijun Ma, Jixin Zhong, Wei Tu, Shiliang Li, Jun Chen
Molecular Biomedicine.2024;[Epub] CrossRef
Efficacy and safety of moderate-intensity rosuvastatin plus ezetimibe versus high-intensity rosuvastatin monotherapy in the treatment of composite cardiovascular events with hypercholesterolemia: A meta-analysis
Lingyan Liu, Yongkun Deng, Lei Li, Xingbiao Yang, Zhaoheng Yin, Yong Lai, Jaspinder Kaur
PLOS ONE.2024; 19(11): e0310696. CrossRef